Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice

• DOI: 10.1111/exd.14890
• Publication Date: 2023-07-21T03:09:33Z
• Authors: Jian Zhou; Yuan Yuan; Yanhua Liu; Mengyang Chu; Huan Liu; Qian Liu; Rui Wang; Shuai Shao; Gang Wang; Chen Yu

Abstract A number of randomized controlled trials and real‐world studies have demonstrated the effectiveness safety secukinumab in treatment moderate to severe psoriasis, whereas data on a large cohort Chinese patients long‐term practice are limited. This was single‐centre, uncontrolled, single‐arm, prospective, observational study that included 254 psoriatic treated with between September 2019 December 2022. Demographic clinical characteristics patients, response adverse events were evaluated. The 75% improvement Psoriasis Area Severity Index score (PASI 75), PASI 90, 100 300 mg group at 12 weeks 91.7%, 74.0% 39.7% respectively, increasing 94.5%, 74.5% 47.6% 52 weeks. High body mass index (BMI), previous exposure biologic therapies history conventional systemic associated lower rates response. During period, 68 reported 83 (AEs) most frequent AEs eczematous lesions. Up 14.5% withdrew due disease remission combined inconvenient transportation during COVID‐19 pandemic rate psoriasis exacerbation after infection 24.3% (17/70). confirmed high plaque an acceptable profile.